Buy & Sell Monster Beverage Corp (MNST) – Monster Beverage Corp Price Today
Aura AI Summary
Key Stats
- $90.97BMarket Cap
- Consumer StaplesSector
- -3.83%3M Drawdown
- $89.27BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 67 daysTypical Hold Time
Monster Beverage Corp (MNST) is currently valued at a market capitalization of $90.97B, with an enterprise value of $89.27B. Over the past 52 weeks, Monster Beverage Corp has traded between a low of $58.65 and a high of $93.51, highlighting its annual price range. Over the past three months, Monster Beverage Corp has recorded a drawdown of -3.83%, reflecting recent price volatility. On average, investors hold Monster Beverage Corp for approximately 67 days, indicating typical investor behavior on the platform.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Most Recent News
ASE Technology sees AI chip demand boost but insider selling and high valuation raise caution.
ASE Technology Holding Co Ltd reported strong growth driven by demand for AI chip packaging, with gross margins rising to 20.1% from 16.8% year-over-year. The company expects its advanced packaging revenue to exceed $3.5 billion in 2026, reflecting r...
Over 20 pharma firms actively develop 25+ drugs for acute kidney injury treatment, signaling strong pipeline growth.
More than 20 pharmaceutical companies are actively researching and developing over 25 drugs for acute kidney injury (AKI), a condition causing sudden kidney function decline. Key players like AstraZeneca and Akebia Therapeutics are advancing therapie...
Law firm probes fairness of shareholder deals in Dana, Roku, TruBridge, Affinity Bancshares sales
Halper Sadeh LLC is investigating whether shareholders of Dana Incorporated, Roku, TruBridge, and Affinity Bancshares are receiving fair treatment in their companies' proposed sales. The firm highlights potential conflicts where insiders might gain b...
